ANTX · AN2 Therapeutics, Inc.
Market Cap
$210.57M
Shares
37.74M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.58
Open$5.67
Day$5.40–5.78
52W close$1.03–6.28
Avg vol 30d212K
Short int2.2M · 5.9% float · 10.1d
Short vol73%
Last earningsMay 19, 2026
DataMar 2022–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+71%
above
Price vs 50-day avg
+6%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
87%
near high
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+6%
trailing
YTD return
+389%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$24.8K over 90 days · 100% sells
Short interest
Falling
5.89% of float · ▼ -6.5% MoM · 10.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
132%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+71%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
87%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$24.8K over 90 days · 100% sells
Short interest
Falling
5.89% of float · ▼ -6.5% MoM · 10.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $6 · 87%
Range high $6
vs 200-day avg +71%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | $79.9M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANTX
this stock
AN2 Therapeutics, Inc.
|
$210.57M | +389.5% | — | — | 5.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANTX | -4.0% | +4.3% | +6.3% | +4.3% | +389.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.4% | +1.3% | -7.1% | +1.3% | +376.7% |
Key facts
CIK
1880438
CUSIP
037326105
13F (30d)
62 filings
62 filers
Visit website
Investor relations